Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies.

Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman AS, Burk RD, Schiffman M.

Int J Cancer. 2012 May 1;130(9):2111-7. doi: 10.1002/ijc.26211. Epub 2011 Aug 5.

2.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
3.

Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.

Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M.

Lancet. 2011 Nov 26;378(9806):1868-73. doi: 10.1016/S0140-6736(11)61522-5. Epub 2011 Nov 1.

PMID:
22051739
4.

Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.

Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P.

Obstet Gynecol. 2007 Jun;109(6):1325-31.

PMID:
17540804
5.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
6.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

7.

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ.

Lancet Oncol. 2012 Jan;13(1):78-88. doi: 10.1016/S1470-2045(11)70296-0. Epub 2011 Dec 14.

PMID:
22177579
8.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

9.
10.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
11.

The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605. Epub 2014 Apr 15.

12.

High-risk human papillomavirus among HIV-infected women with normal cervical cytology: a pilot study in Jos, Nigeria.

Musa J, Taiwo B, Achenbach C, Olugbenga S, Berzins B, Sagay AS, Idoko JA, Kanki PJ, Murphy RL.

Arch Gynecol Obstet. 2013 Dec;288(6):1365-70. doi: 10.1007/s00404-013-2885-x. Epub 2013 May 23.

PMID:
23700253
13.

HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.

Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A.

JAMA. 2000 Jan 5;283(1):81-6.

PMID:
10632284
14.

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.

Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E.

PLoS One. 2016 Jan 20;11(1):e0147326. doi: 10.1371/journal.pone.0147326. eCollection 2016.

15.
16.

Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities.

Gage JC, Schiffman M, Solomon D, Wheeler CM, Gravitt PE, Castle PE, Wentzensen N.

Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1095-101. doi: 10.1158/1055-9965.EPI-12-1455. Epub 2013 Apr 19.

17.

HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT.

JAMA. 2000 Jan 5;283(1):87-93.

PMID:
10632285
18.

Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.

Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A.

BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8. doi: 10.1111/1471-0528.12272. Epub 2013 Jun 21.

19.

Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-Year follow-up of the Guanacaste cohort.

Rodríguez AC, Ávila C, Herrero R, Hildesheim A, Sherman ME, Burk RD, Morales J, Alfaro M, Guillén D, Trejos ME, Vargas RM, Torres G, Schiffman M.

Int J Cancer. 2017 Apr 15;140(8):1926-1934. doi: 10.1002/ijc.30614. Epub 2017 Feb 7.

PMID:
28120391
20.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804

Supplemental Content

Support Center